PepsiCo hits the GLP-1 firewall

Equities 4 minutes to read
Picture of Peter Garnry
Peter Garnry

Chief Investment Strategist

Key points

  • Cost controls boost EPS: PepsiCo's Q3 earnings per share (EPS) grew 3% year-over-year to $2.31, despite a miss on organic revenue growth (1.3% vs. 3% estimated), thanks to strong cost control measures. This short-term strategy helped profitability but raises concerns about long-term growth potential.

  • Obesity drug impact: The company is not addressing the potential long-term impact of GLP-1 drugs on the consumption of sugar and processed foods, which is a key risk as these medications are increasingly used to combat obesity, leading to reduced demand for PepsiCo's core products.

  • Long-term structural headwinds: PepsiCo’s reliance on cost-cutting over investments could lead to declining growth, especially in light of falling U.S. obesity rates and structural challenges in the food industry, further amplified by the rise of obesity drugs. Investors are cautious about the long-term viability of this strategy.

PepsiCo beats on EPS as cost control is favoured over investments

PepsiCo reported Q3 results this Tuesday with shares gaining despite a miss on organic revenue coming in at 1.3% YoY vs est. 3%. Through effective cost controls PepsiCo was able to deliver earnings per share of $2.31 up 3% YoY. I still don’t get why investors are willing to reward PepsiCo for these results. Organic revenue growth is one of the key shareholder value drivers and this factor is deteriorating fast at PepsiCo. The stock’s total return has underperformed both the S&P 500 consumer staples sector and the S&P 500 Index over the past five years indicating that the business is structurally facing headwinds.

Our businesses remained resilient in the third quarter, despite subdued category performance trends in North America, the continued impacts related to certain recalls at Quaker Foods North America and business disruptions due to rising geopolitical tensions in certain international markets. Strong cost controls aided our profitability, as we made incremental investments to improve our marketplace competitiveness,” said Chairman and CEO Ramon Laguarta.

This statement is worrying for several reasons. One, the company is completely silent about the GLP-1 drugs impact on obesity rates in the US and thus consumption of sugar and processed foods. This is a red flag when a management is not recognizing obvious threats to the business. The other worrying part of the statement is that PepsiCo’s management has chosen the path of cost controls to mitigate weak demand which can be okay in the short-term, but if it becomes longer term strategy it will lead to relative growth decline and shareholder value destruction down the road. If I was an investor in PepsiCo I would seriously consider the investment case again.

10_pg_1
PepsiCo total return vs S&P 500 and S&P 500 consumer staples | Source: Bloomberg

Why are food companies so afraid of mentioning obesity drugs?

The chart below shows the two divisions in its North America business which account for 56% of total revenue. The beverage business did $7.2bn in Q3 and the Frito-Lay (snacks) did $5.9bn.

I do not think investors need more proof than this to see that there is a significant impact on the business in the past four quarters overlapping with the accelerated use of GLP-1 drugs to combat obesity. The US obesity rate has fallen for the first time in many decades and given the evidence that sugar and processed food are causal drivers of obesity, we can infer that PepsiCo and food industry could face structural headwinds for decades. The food industry has had an easy time for 50 years engineering great tasting food products ensuring moderate and stable growth rates in the developed world. With the new GLP-1 drugs humans for the first time have a firewall to protect themselves from the engineered products that taste so well that we grave more of it than what we need.

The annualized growth rate of the two North American businesses is -1.5% over the past four quarters. If we subtract the inflation rate over that period the business had a real growth rate of -4.7% which is quite a significant reduction in the business. Why are these food and beverage companies so afraid over talking about GLP-1 drugs? Well, the stock is valued at 21.2x earnings so there is an incentive for management to ensure a high valuation to protect the value of their stock options. As soon as management acknowledge the structural headwinds from GLP-1 drugs there will be a significant repricing of the stock which will destroy the value of these stock options.

At the end of the day, PepsiCo, McDonald’s, Coca-Cola etc. must accept the new reality and find a new way to redefine themselves. If not, it all becomes a game of cost control and capital allocation instead of investments and growth. If they choose the cost control strategy over a decade with structural headwinds on revenue it will be difficult to beat the market and over time investors will lose interest in the stock.

9_pg_2

Quarterly Outlook 2024 Q4

01 /

  • Macro Outlook: The US rate cut cycle has begun

    Quarterly Outlook

    Macro Outlook: The US rate cut cycle has begun

    Peter Garnry

    Chief Investment Strategist

    The Fed started the US rate cut cycle in Q3 and in this macro outlook we will explore how the rate c...
  • Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Quarterly Outlook

    Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Althea Spinozzi

    Head of Fixed Income Strategy

  • Equity Outlook: Will lower rates lift all boats in equities?

    Quarterly Outlook

    Equity Outlook: Will lower rates lift all boats in equities?

    Peter Garnry

    Chief Investment Strategist

    After a period of historically high equity index concentration driven by the 'Magnificent Seven' sto...
  • FX Outlook: USD in limbo amid political and policy jitters

    Quarterly Outlook

    FX Outlook: USD in limbo amid political and policy jitters

    Charu Chanana

    Head of FX Strategy

    As we enter the final quarter of 2024, currency markets are set for heightened turbulence due to US ...
  • Commodity Outlook: Gold and silver continue to shine bright

    Quarterly Outlook

    Commodity Outlook: Gold and silver continue to shine bright

    Ole Hansen

    Head of Commodity Strategy

  • FX: Risk-on currencies to surge against havens

    Quarterly Outlook

    FX: Risk-on currencies to surge against havens

    Charu Chanana

    Head of FX Strategy

    Explore the outlook for USD, AUD, NZD, and EM carry trades as risk-on currencies are set to outperfo...
  • Equities: Are we blowing bubbles again

    Quarterly Outlook

    Equities: Are we blowing bubbles again

    Peter Garnry

    Chief Investment Strategist

    Explore key trends and opportunities in European equities and electrification theme as market dynami...
  • Macro: Sandcastle economics

    Quarterly Outlook

    Macro: Sandcastle economics

    Peter Garnry

    Chief Investment Strategist

    Explore the "two-lane economy," European equities, energy commodities, and the impact of US fiscal p...
  • Bonds: What to do until inflation stabilises

    Quarterly Outlook

    Bonds: What to do until inflation stabilises

    Althea Spinozzi

    Head of Fixed Income Strategy

    Discover strategies for managing bonds as US and European yields remain rangebound due to uncertain ...
  • Commodities: Energy and grains in focus as metals pause

    Quarterly Outlook

    Commodities: Energy and grains in focus as metals pause

    Ole Hansen

    Head of Commodity Strategy

    Energy and grains to shine as metals pause. Discover key trends and market drivers for commodities i...

Disclaimer

The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website. This content is not intended to and does not change or expand on the execution-only service. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
Full disclaimer (https://www.home.saxo/legal/disclaimer/saxo-disclaimer)

Saxo Bank A/S (Headquarters)
Philip Heymans Alle 15
2900
Hellerup
Denmark

Contact Saxo

Select region

International
International

Trade responsibly
All trading carries risk. Read more. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more

This website can be accessed worldwide however the information on the website is related to Saxo Bank A/S and is not specific to any entity of Saxo Bank Group. All clients will directly engage with Saxo Bank A/S and all client agreements will be entered into with Saxo Bank A/S and thus governed by Danish Law.

Apple and the Apple logo are trademarks of Apple Inc, registered in the US and other countries and regions. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC.